Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

Study met primary and all key secondary efficacy endpoints

Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.4 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.81)

DT120 ODT was generally well tolerated, with a safety profile consistent with prior clinical experience

Company to host webcast today at 8:00 am EDT

Continue reading

What White Coat Ceremonies Mean for Arizona’s Healthcare Future

Across Arizona, auditorium lights dim, applause swells, and hundreds of aspiring healthcare professionals step forward to mark their entry into patient care. Whether donning crisp white coats or receiving stethoscopes, these ceremonies represent one of medicine’s most poignant rites of passage—a dynamic transition from textbook study to clinical practice. In 2026, these milestones across the Grand Canyon State carry heightened significance, serving as both a personal achievement for students and a vital sign of hope for Arizona’s expanding medical and life sciences infrastructureContinue reading

BioLab Publishes Membrane Wrap Study for Pressure Ulcers